QI-019B Phase 1 Trial for Relapsed/Refractory Multiple Myeloma
Summary
NIH registered Phase 1 trial NCT07539233 evaluating QI-019B Injection in patients with relapsed/refractory multiple myeloma. The single-arm, open-label, single-center study will assess safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the investigational drug.
What changed
NIH registered a new Phase 1 clinical trial for QI-019B, an investigational injection for patients with relapsed/refractory multiple myeloma. The trial is registered as NCT07539233 and will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy.
Healthcare providers and pharmaceutical companies involved in oncology drug development should note this early-phase trial registration as it represents the entry of a new candidate into the relapsed/refractory multiple myeloma treatment pipeline. Sponsors conducting similar oncology programs may want to monitor trial outcomes for competitive intelligence purposes.
Archived snapshot
Apr 20, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
Early Phase 1 NCT07539233 Kind: EARLY_PHASE1 Apr 20, 2026
Abstract
This is a single-arm, open-label, single-center clinical trial to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of QI-019B in patients with relapsed/refractory multiple myeloma.
Conditions: Multiple Myeloma (MM)
Interventions: QI-019B Injection
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.